Skip to main content

Rigel offers services and support for TAVALISSE

RIGEL ONECARE provides dedicated support for patients and practices

RIGEL ONECARE will help patients get started with TAVALISSE

  • By assisting with reimbursement approval, including benefit investigations, prior authorizations, and appeals
  • By determining eligibility and facilitating enrollment in copay and financial assistance programs
  • By communicating with patients to answer questions so they start TAVALISSE with the information they need

 

RIGEL ONECARE will help patients stay on track

  • By connecting with patients through the first several weeks of their treatment to provide any additional support
  • By supporting modifications in treatment plans
  • By notifying you if a patient has stopped taking treatment or has a medical concern

 

RIGEL ONECARE is designed to fit within your practice needs

  • Flexible: TAVALISSE can be fulfilled through in-office dispensing or through specialty pharmacies 
  • Customized: Choose services and method of contact based on what works best for your staff

RIGEL ONECARE is a patient support center sponsored by Rigel Pharmaceuticals, Inc.

 

  • Nurse iconNurse Navigators
  • Talking about money iconReimbursement Specialists
  • Payment iconFinancial and
    Copay Assistance
  • Education iconEducational Materials

Download the RIGEL ONECARE ENROLLMENT FORM

phone

1-833-rigelOC

(1-833-744-3562) or 650-449-8646

MONDAY-FRIDAY FROM 8 am – 8 pm ET

 

Fax1-833-FXrigel

(1-833-397-4435) or 650-449-8682

With TAVALISSE Copay Assistance, eligible patients could pay as little as $15 per prescription

TAVALISSE copay card thumbnail

Patients may qualify* if . . .

  • They have been diagnosed with low platelet counts due to chronic immune thrombocytopenia (ITP) when a prior treatment for ITP has not worked well enough
  • They are 18 years of age or older
  • They have a commercial insurance plan
  • They are not participating in state or federal programs like Medicare Part D, Medicaid, VA/DOD, or Tricare or other state or federal assistance plans

Here’s how to enroll:

  • Visit TAVALISSEcopay.com
  • Follow the steps to complete the enrollment process to determine if patient is eligible
  • Patient should have the copay card available when speaking with the specialty pharmacy

Limitations may apply.*

*Eligible patients, age 18 or older and with a valid prescription, may receive TAVALISSE at a $15 copay for each prescription, if they pay through commercial insurance. The patient will be responsible for any out-of-pocket expenses after the $15,000 annual cap. This offer is not valid for cash-paying patients. This offer is not insurance and offer is valid only for prescriptions filled in the United States and Puerto Rico. Rigel reserves the right to rescind, revoke, or amend this program without notice. Other restrictions may apply. Patient is responsible for applicable taxes, if any.

Enroll Now in the Copay Assistance Program

Indication

TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Important Safety Information

Warnings and Precautions

  • Hypertension can occur with TAVALISSE treatment. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects. Monitor blood pressure every 2 weeks until stable, then monthly, and adjust or initiate antihypertensive therapy for blood pressure control maintenance during therapy. If increased blood pressure persists, TAVALISSE interruption, reduction, or discontinuation may be required.
  • Elevated liver function tests (LFTs), mainly ALT and AST, can occur with TAVALISSE. Monitor LFTs monthly during treatment. If ALT or AST increase to >3 x upper limit of normal, manage hepatotoxicity using TAVALISSE interruption, reduction, or discontinuation.
  • Diarrhea occurred in 31% of patients and severe diarrhea occurred in 1% of patients treated with TAVALISSE. Monitor patients for the development of diarrhea and manage using supportive care measures early after the onset of symptoms. If diarrhea becomes severe (≥Grade 3), interrupt, reduce dose or discontinue TAVALISSE.
  • Neutropenia occurred in 6% of patients treated with TAVALISSE; febrile neutropenia occurred in 1% of patients. Monitor the ANC monthly and for infection during treatment. Manage toxicity with TAVALISSE interruption, reduction, or discontinuation.
  • TAVALISSE can cause fetal harm when administered to pregnant women. Advise pregnant women the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the last dose. Verify pregnancy status prior to initiating TAVALISSE. It is unknown if TAVALISSE or its metabolite is present in human milk. Because of the potential for serious adverse reactions in a breastfed child, advise a lactating woman not to breastfeed during TAVALISSE treatment and for at least 1 month after the last dose.

Drug Interactions

  • Concomitant use of TAVALISSE with strong CYP3A4 inhibitors increases exposure to the major active metabolite of TAVALISSE (R406), which may increase the risk of adverse reactions. Monitor for toxicities that may require a reduction in TAVALISSE dose.
  • It is not recommended to use TAVALISSE with strong CYP3A4 inducers, as concomitant use reduces exposure to R406.
  • Concomitant use of TAVALISSE may increase concentrations of some CYP3A4 substrate drugs and may require a dose reduction of the CYP3A4 substrate drug.
  • Concomitant use of TAVALISSE may increase concentrations of BCRP substrate drugs (eg, rosuvastatin) and P-Glycoprotein (P-gp) substrate drugs (eg, digoxin), which may require a dose reduction of the BCRP and P-gp substrate drug.

Adverse Reactions

  • Serious adverse drug reactions in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, which occurred in 1% of TAVALISSE patients. In addition, severe adverse reactions occurred including dyspnea and hypertension (both 2%), neutropenia, arthralgia, chest pain, diarrhea, dizziness, nephrolithiasis, pain in extremity, toothache, syncope, and hypoxia (all 1%).
  • Common adverse reactions (≥5% and more common than placebo) from FIT-1 and FIT-2 included: diarrhea, hypertension, nausea, dizziness, ALT and AST increased, respiratory infection, rash, abdominal pain, fatigue, chest pain, and neutropenia.

 

Please see full Prescribing Information.

To report side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

Back to the top

Rigel Pharmaceuticals logo

© 2019 Rigel Pharmaceuticals, Inc. All rights reserved.  |  TAVA_ITP-18239 0319

TAVALISSE and RIGEL ONECARE are trademarks of Rigel Pharmaceuticals, Inc. 

RIGEL ONECARE is a patient support center sponsored by Rigel Pharmaceuticals, Inc.

1180 Veterans Blvd, South San Francisco, CA 94080 

Indication

TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Important Safety Information

Warnings and Precautions

  • Hypertension can occur with TAVALISSE treatment. Patients with pre-existing hypertension may be more susceptible to the hypertensive effects. Monitor blood pressure every 2 weeks until stable, then monthly, and adjust or initiate antihypertensive therapy for blood pressure control maintenance during therapy. If increased blood pressure persists, TAVALISSE interruption, reduction, or discontinuation may be required.